SMIM17: A Potential Drug Target for Cancer Treatment (G147670)

Target Name: SMIM17

NCBI ID: G147670

SMIM17

Other Name(s): LOC147670 | small integral membrane protein 17 | Small integral membrane protein 17 | hypothetical protein LOC147670 | SIM17_HUMAN

SMIM17: A Potential Drug Target for Cancer Treatment

SMIM17, short for small molecule inhibitor of myeloid-derived suppressor 17, is a protein that is expressed in various cell types, including human leukemia cells. It has been identified as a potential drug target or biomarker for the treatment of various types of cancer, including leukemia.

SMIM17 is a protein that is characterized by its ability to suppress the activity of myeloid-derived suppressor 17 (MSG1), a protein that is involved in the development and maintenance of mouse hematopoietic stem cells. MSG1 has also been shown to play a role in the development of various types of cancer, including leukemia.

SMIM17 is expressed in various cell types, including human leukemia cells, and has been shown to be involved in the development and maintenance of these cells. It is possible that SMIM17 may be a drug target or biomarker for the treatment of leukemia, as it has been shown to play a role in the development and maintenance of this disease.

In addition to its potential as a drug target or biomarker, SMIM17 may also be of interest to researchers because of its unique structure. SMIM17 is a small molecule that is designed to interact with MSG1, and its structure is optimized to do so. This may make it an attractive target for researchers who are looking for new and effective ways to inhibit the activity of MSG1.

Overall, SMIM17 is a protein that is worth further research as a potential drug target or biomarker for the treatment of leukemia and other types of cancer. Its unique structure and its ability to interact with MSG1 make it an attractive target for researchers who are looking for new and effective ways to inhibit the activity of this protein.

Protein Name: Small Integral Membrane Protein 17

The "SMIM17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMIM17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets